| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC0864 |
| Trial ID | ChiCTR2000033567 |
| Disease | Plasma Cell Neoplasm |
| Altered gene | CD19|BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA/CD19 CAR-T cells |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | Clinical study for anti-BCMA and anti-CD19 double targets CAR-T in the treatment of refractory or recurrent plasma cell tumor |
| Year | 2020 |
| Country | China |
| Company sponsor | The Affiliated Hospital of Xuzhou Medical University |
| Cohort 1 | |||||||
|
|||||||